Related Experiment Videos
[Atrial fibrillation: anticoagulants or not?]
1Centre de cardiologie, Hôpital cantonal universitaire, Genève.
Schweizerische Medizinische Wochenschrift
|September 3, 1994
Summary
For atrial fibrillation patients, anticoagulant therapy significantly reduces stroke risk. Aspirin offers a less potent but safer alternative for specific patient groups, especially the elderly.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation (AF) is a prevalent arrhythmia.
- AF increases embolic stroke risk fivefold in nonrheumatic cases.
- Anticoagulant use in AF lacked consensus; aspirin's role was debated.
Purpose of the Study:
- To evaluate anticoagulant and aspirin efficacy for primary stroke prevention in nonrheumatic AF.
- To assess the risk-benefit profile of anticoagulation versus aspirin.
Main Methods:
- Review of 5 randomized, controlled trials (RCTs) published since 1989.
- Comparison of warfarin or aspirin against placebo for stroke prevention.
- Analysis of moderate anticoagulation levels (INR 1.5-3.0) and bleeding rates.
Main Results:
- Anticoagulant therapy demonstrated significant risk reduction (35-86%) for stroke.
- Aspirin showed a less pronounced risk reduction (15-42%).
- Major bleeding rates with moderate anticoagulation were low (0.8-2.5% annually).
Conclusions:
- Anticoagulant therapy is highly effective for stroke prevention in nonrheumatic AF.
- Aspirin is a viable, safer alternative for elderly patients (>75 years) or those with high bleeding risk.
- Anticoagulation may not be indicated for younger patients (<60 years) with lone AF; individualized decisions are crucial.